‘Most Favored Nation’ Pricing Data May Be Long-Term Impact Of Last-Minute Rule
Executive Summary
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.
You may also be interested in...
New Medicare Payment Models Should Not Be All About Saving Money, CMMI’s Fowler Says
CMS’s Innovation director Elizabeth Fowler wants to ‘reignite’ momentum behind health care system transformation. What does that mean for biopharma?
Medicare Drug Pricing Demonstration Agenda May Be Reshaped By Fowler As CMMI Head
Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.
Stock Watch: New Year, New Politics; Same Old Pricing And Generic Challenges
A positive start to the year for healthcare stocks was accompanied, as usual, by drug price increases. This and the other issues that have been carried over from 2020 remain just as challenging.